How it works
The lead peptide modulates tyrosinase activity, the rate-limiting enzyme in melanin biosynthesis. Ancillary components extend the formulation into adjacent pigmentation pathways and antioxidant signaling in melanocyte cultures. Published work on the components has documented effects on tyrosinase expression, ROS handling in cultured melanocytes, and dermal pigmentation modeling.
Each 80mg vial contains a kojic-acid-coupled peptide complex with ancillary tyrosinase-modulating components, studied collectively for effects on melanogenesis pathways. Full composition on every COA.
Learn more about the science →Certificate of Analysis+
Component-by-component identity, purity, mass spec, endotoxin, finished-blend verification. Third-party ISO-17025.
View full certificate →Specifications+
Storage & handling+
Lyophilized: −20°C, 24 months. Protect from light. Reconstituted: 2–8°C, 21 days. Bacteriostatic water.
We ship in insulated parcels with phase-change cooling and a tamper-evident seal.
FAQs+
How does Klow differ from Glow in research applications?+
Different lead peptides, different downstream targets. Glow: collagen and ECM via GHK-Cu. Klow: pigmentation via tyrosinase modulation.
Will the full composition appear on the COA?+
Yes. Every component named, weighed, verified.
Why the higher mg loading than Glow?+
The lead peptide in Klow has a lower per-mg activity profile than GHK-Cu, so the working concentration is higher.
Is Klow stable in solution longer than Glow?+
Slightly. Without the copper component, Klow tolerates a marginally longer post-reconstitution window — but the operating spec is 21 days at 2–8°C.
What's the typical reconstitution volume?+
Common preparation: 2 mL bacteriostatic water per 80mg vial.
Is Klow subscription-eligible?+
Yes. 15% off on a 60-day cycle.
The research behind this compound, cited in full.
Provided for context only. None of the studies cited below evaluate hábit material specifically; they document the published literature on the compound and its mechanism. Research-use claims are not therapeutic claims.
- [01] Schurink M. et al. Peptides 28 (2007): 485–495.
- [02] Pillaiyar T. et al. J Enzyme Inhib Med Chem 32 (2017): 403–425.
- [03] PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
- [04] α-MSH Related Peptides: A New Class of Anti-Inflammatory and Immunomodulating Drugs
Verified buyer notes
Initials only — every quote is verified against an order record. We don’t ghost-write reviews.
“COA matched what we ran in-house. Powder reconstituted clean, no haze. Did exactly what we needed it to.”
“Switched after two bad lots from a previous source. Three orders in, zero issues.”
“Asked support a purity question and got the raw HPLC trace back within the hour. That transparency is why we reorder.”